Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 6

  • 1 638 clinical trials
  • 557 recruiting
  • 289 conditions
  • 28 countries

Conditions in this area

289 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy45Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Interstitial lung disease28Sjogren's syndrome28Immune thrombocytopenia27Endocrine ophthalmopathy26Vitiligo23Hereditary angioedema22IgA nephropathy22Axial spondyloarthritis21+265

Clinical trials in Immune system disorders

1 638 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 638 clinical trials

HIV infection

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

Colitis ulcerative

Recruiting
InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Systemic scleroderma

Recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bi 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Rheumatoid arthritis+3

Recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:T Lymphocytes Transduced With A Rv-Sfg.cd19.Cd28.4-1Bbzeta Retroviral Vector
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Rheumatoid arthritis

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tocilizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cholangitis sclerosing

Recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

HIV infection

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

HIV infection

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Gilead Sciences Inc.

Interstitial lung disease+1

Recruiting
InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:TX000045

Type 1 diabetes mellitus

Recruiting
Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Immunocore Limited

Colitis ulcerative

Recruiting
Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab39 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.